

Product datasheet for RC208522L2V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

TAB1 (NM_006116) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type: Lentiviral Particles

Product Name: TAB1 (NM_006116) Human Tagged ORF Clone Lentiviral Particle

Symbol: TAB

Synonyms: 3'-Tab1; MAP3K7IP1

Mammalian Cell

Selection:

None

Vector: pLenti-C-mGFP (PS100071)

Tag: mGFP

ACCN: NM_006116 **ORF Size:** 1512 bp

ORF Nucleotide

OTI Disclaimer:

Sequence:

The ORF insert of this clone is exactly the same as(RC208522).

The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing

variants is recommended prior to use. More info

OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression

varies depending on the nature of the gene.

RefSeg: NM 006116.2

 RefSeq Size:
 3240 bp

 RefSeq ORF:
 1515 bp

 Locus ID:
 10454

 UniProt ID:
 Q15750

 Cytogenetics:
 22q13.1

Domains: PP2C

Protein Families: Druggable Genome





TAB1 (NM_006116) Human Tagged ORF Clone Lentiviral Particle - RC208522L2V

Protein Pathways: MAPK signaling pathway, NOD-like receptor signaling pathway, Toll-like receptor signaling

pathway

MW: 54.6 kDa

Gene Summary: The protein encoded by this gene was identified as a regulator of the MAP kinase kinase

kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli. Alternatively spliced transcript variants

encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]